Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV hepatitis B immunoglobulin (pH4) + lamivudine to prevent HBV recurrence after liver transplantation
CTR20131641Phase 3Completed
- Sponsor
- Wuhan Institute of Biological Products
- Start
- Oct 2014
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of hepatitis B immune globulin in hepatitis B (HBV), Hepatitis B-related liver disease, Hepatitis B virus recurrence, sponsored by Wuhan Institute of Biological Products. Started Oct 2014; status: completed.
02
Drugs
hepatitis B immune globulin
03
Conditions
hepatitis B (HBV)Hepatitis B-related liver diseaseHepatitis B virus recurrence
Beyond the preview
Go deeper on CTR20131641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131641.